We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

GE Launches Drawbridge Health to Transform Blood Collection

By LabMedica International staff writers
Posted on 05 Dec 2017
GE Healthcare (Chicago, IL, USA) has introduced Drawbridge Health, a privately held healthcare technology company, which is developing a people-friendly system to integrate draw, collection and stabilize blood samples into a single device. The technology which integrates engineering and proprietary chemistries is also being developed to support room temperature shipping and streamlined downstream processing, thus ensuring reliable, accurate results.

The Drawbridge solution will allow healthcare providers and diagnostic testing companies to deliver a superior patient experience by eliminating the need for phlebotomy and travel to blood draw centers. Drawbridge expects its blood draw solution to alter the market for patients and healthcare providers by broadening the availability and access for molecular tests for a variety of diseases, as well as providing a convenient way to monitor overall health, therapy response and disease progression.

“At GE we share technology, markets, structure and knowledge across our varied businesses, which uniquely positions us to tackle many issues, including this one,” said Risa Stack, Managing Director of New Business Creation, GE Ventures. “With Drawbridge Health, we are combining technology from GE Global Research, expertise from GE Healthcare and business models from GE Ventures to offer a simple, safe and more efficient solution that can help save time, money and lives.”

“At Drawbridge Health, we have a tremendous opportunity to uniquely enable not only effortless access to diagnostic testing, but to also transform how diagnostics companies and healthcare providers interact with their patient-consumers,” said Lee McCracken, CEO, Drawbridge Health.

“The current sample testing process is inconvenient and challenging for patients and medical providers, alike. It requires clinical processing equipment, often a technician specifically trained to draw blood, plus a trip to the doctor’s office or hospital. By combining world class GE technology and a talented founding team to address an important market need, Drawbridge Health is well positioned to transform diagnostic testing for healthcare stakeholders, testing laboratories, patients and consumers.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+

Latest Industry News

Hologic and Inpeco Partner to Advance Molecular Laboratory Automation in Europe
05 Dec 2017  |   Industry

Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection
05 Dec 2017  |   Industry

Myriad Genetics to Sell Prenatal Testing Portfolio to Labcorp
05 Dec 2017  |   Industry